Position in RPRX
as of Mar 31, 2026
· filed Apr 28, 2026
Position Value
$259,853
New position
Shares Held
5,417
first reported quarter
Ownership
0.001%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 97.26786043935758.ToString("F0")%
Shared 0.ToString("F0")%
None 2.7321395606424224.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026DGS Capital Management, LLC holds $3,182,420 across 10 Biotechnology names. RPRX ranks #7 (8.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
6,682 | $628,909 | |
| 2 | EXEL |
Exelixis, Inc.
|
14,116 | $605,435 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,310 | $584,967 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
415 | $320,645 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
1,536 | $290,380 | |
| 6 | GMAB |
Genmab A/S
|
10,173 | $272,941 | |
| 7 | RPRX |
Royalty Pharma plc
This page
|
5,417 | $259,853 | |
| 8 | ZVRA |
Zevra Therapeutics, Inc.
|
14,810 | $138,029 |
All Filings in RPRX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $259,853 | 5,417 | Shares | Sole | 2026-04-28 | |
| No filing history on record for this holder in this stock. | ||||||